EVH Stock Recent News

Evolent Health, Inc. (NYSE:EVH ) Q4 2024 Earnings Conference Call February 20, 2025 5:00 PM ET Company Participants Seth Frank - Vice President, Investor Relations Seth Blackley - Chief Executive Officer John Johnson - Chief Financial Officer Conference Call Participants Matthew Gillmor - KeyBanc Charles Rhyee - TD Cowen Andrea Alfonso - UBS Jailendra Singh - Truist Securities Ryan Daniels - William Blair Jeff Garro – Stephens Anne Samuel - J.P. Morgan Richard Close - Canaccord Genuity Jessica Tassan - Piper Sandler David Larsen - BTIG Daniel Grosslight – Citi Matthew Shea - Needham Operator Welcome to the Evolent Earnings Conference Call for the Fourth Quarter and Year End December 31, 2024.

The headline numbers for Evolent Health (EVH) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Evolent Health (EVH) came out with a quarterly loss of $0.02 per share in line with the Zacks Consensus Estimate. This compares to earnings of $0.23 per share a year ago.

Revenue of $646.5 million for the three months ended December 31, 2024 and $2,554.7 million for the year ended December 31, 2024, representing 16.3% and 30.1% growth over 2023, respectively. Net loss attributable to common shareholders of Evolent Health, Inc. of $30.6 million for three months ended December 31, 2024 and $93.5 million for the year ended December 31, 2024, resulting in a net loss margin of (4.7)% and (3.7)%, respectively.

Beyond analysts' top -and-bottom-line estimates for Evolent Health (EVH), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.

Evolent Health (EVH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Richard " Rick "  Jelinek to Be Named Chair of the Board at 2025 Annual Meeting Company Continues Board Refreshment Efforts with Brendan Springstubb ' s Appointment as New Independent Director WASHINGTON , Feb. 4, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH) ("Evolent"), a company focused on achieving better health outcomes for people with complex conditions, today announced changes to its Board of Directors as part of the Company's ongoing commitment to strong corporate governance and to collaboration with shareholders. Rick Jelinek, who joined the Evolent Board as an independent director in 2023, will be named Chair of the Board at the 2025 Annual Meeting, succeeding Cheryl Scott.

DEC, ERO and EVH have been added to the Zacks Rank #5 (Strong Sell) List on January 30, 2024.

Company to Participate in Upcoming Conferences WASHINGTON , Jan. 27, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its fourth quarter 2024 financial results on Thursday, February 20, 2025, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference call found on Evolent's investor relations website, https://ir.evolent.com.

Truist analyst Jailendra Singh caught up with Evolent Health post its presentation at an investor healthcare conference and also noted that the company released an 8-K earlier in the week outlining some preliminary views on 2025. Evolent is encouraging investors to use Q4 EBITDA run-rate as the baseline for 2025 and the firm now sees the company's 2025 guidance range coming in "significantly below consensus," the analyst tells investors. Using about $25M of Q4 EBITDA as a baseline, the firm infers that Evolent is suggesting a potential initial FY25 EBITDA range of $140M-$170M, said the analyst, who has a Buy rating and $20 price target on the shares. In Wednesday trading, Evolent shares slid 10% to $10.02.